Photo by bagasvg from unsplash
In January of 2023, the first adalimumab biosimilar became available in the United States for treatment of inflammatory bowel disease (IBD). Seven more adalimumab biosimilars are set to become available… Click to show full abstract
In January of 2023, the first adalimumab biosimilar became available in the United States for treatment of inflammatory bowel disease (IBD). Seven more adalimumab biosimilars are set to become available over the summer and fall of the same year, with more likely to follow. Based on our previous experiences with infliximab biosimilars that identified a number of challenges, pediatric gastroenterologists should be aware of several similarities and differences when prescribing an adalimumab biosimilar.
Keywords:
biosimilars considerations;
considerations pediatric;
wave adalimumab;
riding wave;
pediatric gastroenterologists;
adalimumab biosimilars
Journal Title: Journal of Pediatric Gastroenterology and Nutrition
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Pediatric Gastroenterology and Nutrition
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!